Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
34.59m
Last Price
$0.88
52-Week Range
$0.66 - $1.93
08/11/2025 02:08 PM EDT